ERIN STOCKMAN: Open Payments
NPI 1104218486 · REDLANDS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$762 in 23 payments from 8 companies in 2025. Trend: 2023 $263 · 2024 $21 · 2025 $762
Food & beverage: $762
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 2 | $250 |
| Novartis Pharmaceuticals Corporation | 12 | $210 |
| Regeneron Healthcare Solutions, Inc. | 3 | $146 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $53 |
| Cycle Pharmaceuticals Inc | 1 | $32 |
| Optinose US, Inc. | 1 | $28 |
| Arcutis Biotherapeutics, Inc. | 1 | $26 |
| AstraZeneca Pharmaceuticals LP | 1 | $17 |
Products named: DUPIXENT, Rhapsido, CUVITRU, Sajazir, Xhance, Zoryve, BREZTRI, XOLAIR.
Industry payments across CA — which companies pay providers there.
